CODEXIS INC. - COMMON STOCK

Codexis Announces CEO Transition Effective August 9, 2022

18 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)

14 Jul 2022 15:06:00 By Nasdaq GlobeNewswire

Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance

14 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides

17 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Codexis to Participate in Upcoming Healthcare Conferences

25 May 2022 15:05:00 By Nasdaq GlobeNewswire

Codexis to Participate in Upcoming Healthcare Conferences

17 May 2022 15:05:00 By Nasdaq GlobeNewswire

Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting

16 May 2022 07:00:02 By Nasdaq GlobeNewswire

Codexis Reports First Quarter 2022 Financial Results

05 May 2022 15:05:03 By Nasdaq GlobeNewswire

Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting

02 May 2022 15:35:00 By Nasdaq GlobeNewswire

Codexis to Report First Quarter 2022 Financial Results on May 5

21 Apr 2022 15:05:01 By Nasdaq GlobeNewswire

Codexis and seqWell Announce Strategic Investment and Partnership Initiation

21 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis

12 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Codexis to Participate in the Cowen 42nd Annual Health Care Conference

01 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results

24 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

10 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria

24 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference

05 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

15 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021

22 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Codexis to Participate in Upcoming Virtual Healthcare Conferences

19 Nov 2021 07:00:00 By Nasdaq GlobeNewswire